GlassScriptPhysician profile
Ronald O Rigor
NPI 1700835675
$1,728.56
in general payments reported to CMS, 2019-2025
14 companies · $49.59 in 2025
The $49.59 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $252 · 2021: $73.89 · 2022: $267 · 2023: $387 · 2024: $228 · 2025: $49.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $664.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $506.55 | 2021-2024 | |
| Allergan, INC. | $246.03 | 2019-2022 | |
| Pfizer INC. | $158.50 | 2019-2025 | |
| Genentech USA, INC. | $157.97 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $148.15 | 2019-2024 | Odomzo |
| Merz North America, INC. | $140.88 | 2020-2022 | |
| Galderma Laboratories, L.P. | $125.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $65.78 | 2023-2024 | Dupixent |
| Celgene Corporation | $44.24 | 2019 | |
| Amgen INC. | $31.55 | 2024 | Otezla |
| Leo Pharma INC. | $27.41 | 2021 | |
| Mayne Pharma Commercial LLC | $27.33 | 2019 | |
| Dermira, INC. | $25.51 | 2019 | |
| Paratek Pharmaceuticals, INC. | $23.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Rigor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.